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Background: Acetylation of lysine residues in histone tails plays an important role in the regulation of gene
transcription. Bromdomains are the readers of acetylated histone marks, and, consequently, bromodomain-
containing proteins have a variety of chromatin-related functions. Moreover, they are increasingly being recognised
as important mediators of a wide range of diseases. The first potent and selective bromodomain inhibitors are
beginning to be described, but the diverse or unknown functions of bromodomain-containing proteins present
challenges to systematically demonstrating cellular efficacy and selectivity for these inhibitors. Here we assess the
viability of fluorescence recovery after photobleaching (FRAP) assays as a target agnostic method for the direct
visualisation of an on-target effect of bromodomain inhibitors in living cells.
Results: Mutation of a conserved asparagine crucial for binding to acetylated lysines in the bromodomains of
BRD3, BRD4 and TRIM24 all resulted in reduction of FRAP recovery times, indicating loss of or significantly reduced
binding to acetylated chromatin, as did the addition of known inhibitors. Significant differences between wild type
and bromodomain mutants for ATAD2, BAZ2A, BRD1, BRD7, GCN5L2, SMARCA2 and ZMYND11 required the
addition of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) to amplify the binding
contribution of the bromodomain. Under these conditions, known inhibitors decreased FRAP recovery times back
to mutant control levels. Mutation of the bromodomain did not alter FRAP recovery times for full-length CREBBP,
even in the presence of SAHA, indicating that other domains are primarily responsible for anchoring CREBBP to
chromatin. However, FRAP assays with multimerised CREBBP bromodomains resulted in a good assay to assess the
efficacy of bromodomain inhibitors to this target. The bromodomain and extraterminal protein inhibitor PFI-1 was
inactive against other bromodomain targets, demonstrating the specificity of the method.
Conclusions: Viable FRAP assays were established for 11 representative bromodomain-containing proteins that
broadly cover the bromodomain phylogenetic tree. Addition of SAHA can overcome weak binding to chromatin,
and the use of tandem bromodomain constructs can eliminate masking effects of other chromatin binding
domains. Together, these results demonstrate that FRAP assays offer a potentially pan-bromodomain method for
generating cell-based assays, allowing the testing of compounds with respect to cell permeability, on-target efficacy
and selectivity.
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Posttranslational modification of histones represents an
important mechanism for the epigenetic regulation of
gene expression. ε-N-acetyl lysine marks on histones can
be ‘written’ and ‘erased’ by histone acetyltransferases
(HATs) and histone deacetylases (HDACs), respectively,
and are ‘read’ by bromodomains. Sixty-one unique bromo-
domains have been identified in forty-two diverse human
proteins, which function as transcriptional regulators,
chromatin remodelling factors, splicing factors, scaffold
proteins and signal transducers, or have additional epi-
genetic functions such as methyltransferase or HAT acti-
vity [1]. In many cases however, the function of a specific
bromodomain-containing protein remains unknown. In
addition, bromodomain-containing proteins have been
implicated in a wide range of diseases. Overexpression of
numerous family members has been reported in a variety
of cancers [2-6], and translocations of BRD3 or BRD4
with NUT and CREBBP with MLL, MOZ or MORF have
been observed in NUT midline carcinoma [7] and acute
myeloid and lymphoblastic leukaemia [8], respectively.
Bromodomain-containing proteins have also been
implicated in proinflammatory processes as well as in a
number of neurological diseases [2,3]. The involvement
of bromodomain-containing proteins in such a wide range
of diseases makes them attractive therapeutic targets, and,
as a result, a number of bromodomain inhibitors have
been entered into clinical trials [9-13].
Although bromodomains exhibit considerable sequence
diversity, they share a conserved fold that comprises a
left-handed bundle of four α-helices, which form the
acetyl-lysine binding pocket. A highly conserved aspa-
ragine residue in this binding pocket is typically res-
ponsible for anchoring the acetyl-lysine side chain via
hydrogen bonding, but can in some cases be replaced
by other amino acids, including threonine or tyrosine
[1]. This deep structurally conserved and largely hydro-
phobic cavity provides a viable target for the develop-
ment of acetyl-lysine competitive inhibitors. We have
previously described biochemical assays for the iden-
tification of small-molecule inhibitors of several diverse
bromodomains [14]. A key step in the development of
bromodomain inhibitors is the demonstration of cellular
efficacy for the target of interest, which is complicated by
the functional diversity, or even unknown function, of
many bromodomain-containing proteins.
Fluorescence recovery after photobleaching (FRAP) has
evolved into a powerful confocal microscopy technique in
which a portion of a live cell bearing fluorescently labelled
molecules is photobleached by a high-intensity laser pulse
and the migration of labelled molecules back into the
bleached area is monitored over time [15]. This technique
can be applied to the analysis of bromodomain-binding to
chromatin, where- the protein of interest is fused to afluorescent protein, such as green fluorescent protein
(GFP). After photobleaching, diffusion of unbleached
protein back into the bleached region is retarded by
protein binding to chromatin and chromatin-associated
complexes and is therefore slower compared to a freely
diffusible molecule. Thus, the time taken for recovery is
related to protein affinity, and an inhibitor of protein bind-
ing would be expected to reduce recovery time [16].
Since bromodomains lack any catalytic activity that
could otherwise be monitored and the common deno-
minator in the function of most bromodomain-
containing proteins is chromatin association, FRAP rep-
resents a target agnostic method for detecting bromodo-
main inhibition. Furthermore, direct visualisation of an
on-target effect in the nucleus of live cells also offers the
advantage of eliminating artefacts associated with
ex vivo assays. Indeed, we have previously described dis-
placement of BRD4 from chromatin by small-molecule
inhibitors in a FRAP-based assay [17,18]. Here we inves-
tigate whether FRAP assays have the potential to be used
broadly across the bromodomain family for establishing
cellular efficacy of inhibitors.
Results and discussion
Bromodomain-containing proteins have been identified as
attractive therapeutic targets [3]. In order to assess the on-
target effect of developed inhibitors in the intact cell, we
employed FRAP experiments for a variety of these targets
broadly covering the branches of the bromodomain tree [1]
(Figure 1B). We started with BRD4, for which we have pre-
viously demonstrated target engagement in the cell [17,18].
BRD4, which contains two bromodomains (Figure 1A),
binds to acetylated histones and remains associated with
chromatin throughout mitosis, providing a mechanism
for epigenetic memory that maintains efficient postmi-
totic transcription of ‘bookmarked’ genes [19]. During
interphase, BRD4 also plays a key role in the regulation
of transcriptional elongation by recruiting the positive
transcription elongation factor b, or P-TEFb, complex to
promoters and thereby facilitating the phosphorylation
and activation of RNA polymerase II [20]. Although
these known functions provide possible downstream
biological readouts for BRD4 bromodomain inhibition,
FRAP assays allow the disruption of chromatin binding
to be directly visualised in living cells.
Full-length, GFP-tagged wild-type and mutant BRD4
proteins localised exclusively to the nucleus but were
excluded from the nucleoli (Figure 2A), as has been
reported for endogenous BRD4 [21]. Photobleaching of a
13.6 μm2 area of the nucleus (approximately 6%) re-
sulted in gradual recovery to >90% of initial intensities
(Figure 2B), indicating that the majority of the GFP-
tagged protein is mobile, with a half recovery time (t½)






















































































































Figure 1 Bromodomain phylogenetic tree and domain structure of representative family members. (A) Domain organization of
bromodomain-containing proteins for which fluorescence recovery after photobleaching (FRAP) assays are described herein. Protein length in
amino acids is shown at the right of each protein. The identities of the different domains are given in the legend at the bottom. (B) The
structure-based phylogenetic tree of the human bromodomain family according to Filippakopoulos et al. [1]. The different families are named by
Roman numerals (I to VIII). Proteins for which FRAP assays are described herein are highlighted in red.
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first bromodomain of BRD4 or N443F in the second
bromodomain of BRD4) or both bromodomains (N140F
and N433F) at the conserved asparagine that forms a
hydrogen bond with acetylated lysines of histone tails
resulted in a significantly reduced t½ (P < 0.05). This
implies that BRD4 is being anchored to chromatin, at
least in part, via the bromodomains. Previous in vitro
studies have demonstrated that the first bromodomain
of BRD4 binds more tightly to some histone acetylation
sites than the second domain [1], and this trend was also
seen in FRAP, although significance was not reached by
analysis of variance (ANOVA) multiple comparisons
testing. The observed reduction in FRAP recovery times
between the wild type and mutants demonstrates that a
measurable assay window should exist for the displace-
ment of wild-type BRD4 from chromatin by small-
molecule inhibitors of the bromodomain. Indeed, thiswas seen for the bromodomain and extraterminal
protein (BET) bromodomain inhibitor JQ1 [17], which
reduced t½ to levels similar to the double-mutant when
added 1 hour prior to FRAP. The short incubation time
also argues strongly that the observed effects of JQ1 are
due to direct displacement of BRD4 rather than to
downstream consequences of inhibition of endogenous
BRD4.
Similar results were also observed in FRAP for BRD3
[22,23], another member of the BET subfamily contain-
ing two bromodomains (Figure 2D). t½ was significantly
reduced relative to the wild type for first bromodomain
(N115F), second bromodomain (N390F) and double-
bromodomain (N115F/N390F) mutants (P < 0.05). A
second BET inhibitor based on a different chemotype,
PFI-1 [18,24], reduced t½ to levels similar to that of the
double-mutant, confirming in the FRAP assay the potency
observed in vitro against both bromodomains.

































































































































Figure 2 Fluorescence recovery after photobleaching assays detect mutation of the bromodomains and inhibition by small molecules.
(A) Nuclei of U2OS cells transfected with plasmids encoding green fluorescent protein fused to wild-type BRD4, BRD4 bromodomain mutants or
wild-type BRD4 treated with JQ1. The bleached area is indicated by a red circle. (B) Time dependence of fluorescence recovery in the bleached
area for the BRD4 fluorescence recovery after photobleaching (FRAP) assay. Curves represent the means at each time point of at least ten cells in
each group. Half-times of fluorescence recovery (t½) in FRAP assays for BRD4 (C) and BRD3 and TRIM24 (D). Bars represent the mean t½
calculated from individual recovery curves of at least ten cells per group, and error bars depict the standard error of the mean. Where an inhibitor
is used, concentration is 1 μM. wt, Wild type; N###F, Bromodomain mutants, indicating substitution made. *P < 0.05, significant difference from
wild type.
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a RING domain, two B-box domains and a coiled-coil re-
gion, that is characteristic of the TRIM family, in addition
to the C-terminal PHD-bromodomain cassette (Figure 1A).
TRIM24 acts as a transcriptional regulator, binding to
chromatin and interacting with several nuclear receptors
and coactivators [25]. A clear reduction in t½ was seen
between wild-type TRIM24 (20.7 ± 1.8 seconds) and the
N981F mutant (2.8 ± 0.3 seconds) (Figure 2D). Small-
molecule inhibitors of the TRIM24 bromodomain are yet
to be described, but the pronounced difference between
the wild type and bromodomain mutant suggest that
this FRAP assay would be sensitive to such compounds.
Of note is the long recovery time of the wild-type
TRIM24, despite the use of a small bleach area (2.5 μm2),
which is consistent with previous in vitro findings where
TRIM24 exhibited the greatest reported affinity between abromodomain and an acetylated histone peptide [3,26].
This affinity appears to be conferred by the PHD and
bromodomain acting as a single functional unit for the
combinatorial recognition of unmodified H3K4 and
H3K23ac within the same histone tail.
SMARCA2 is a central component of the SWI/SNF
chromatin remodelling complex and contains multiple
chromatin binding domains [27] (Figure 1A). When FRAP
experiments were performed with full-length SMARCA2,
no significant difference in recovery times could be ob-
served between the wild type and bromodomain mutants
(see Figure 3C and Additional file 1: Figure S1), indicating
that SMARCA2 chromatin binding was not being prima-
rily driven through bromodomain interactions in unstimu-
lated U2OS cells. However, preincubation with the HDAC
inhibitor suberoylanilide hydroxamic acid (SAHA; 0.625
to 10 μM), which would be expected to increase the global
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Figure 3 Fluorescence recovery after photobleaching assays performed with the addition of suberoylanilide hydroxamic acid to
establish a robust assay window. (A) Nuclei of U2OS cells transfected with plasmids encoding green fluorescent protein chimerised to
wild-type or mutant SMARCA2, with or without 2.5 μM suberoylanilide hydroxamic acid (SAHA) and the inhibitor PFI-3. The bleached area is
indicated by a red circle. (B) Time dependence of fluorescence recovery in the bleached area for the SMARCA2 fluorescence recovery after
photobleaching (FRAP) assay. Half-times of fluorescence recovery (t½) in the FRAP assays for SMARCA2 (C), BAZ2A, BRD7, ATAD2, GCN5L2,
ZMYND11 and BRD1 (D) and BRD3 (E). Bars represent the mean t½ calculated from individual recovery curves of at least ten cells per group,
and error bars depict the standard error of the mean. Where an inhibitor is used, concentration is 1 μM, except GSK2801, which is 5 μM. wt,
Wild type; X####F, Bromodomain mutants, indicating substitution made. †Addition of 2.5 μM SAHA. *P < 0.05, significant difference from wild type†.
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increase in t½ (see Additional file 1: Figure S1). This
increase in FRAP recovery time was clearly being driven by
interaction with the bromodomain, since the N1464F
mutant did not respond to SAHA preincubation (P > 0.05).
Although the greatest effect of SAHA preincubation was
seen at higher concentrations, cytotoxicity was also
pronounced above 2.5 μM (data not shown), reducing the
number of viable cells available for FRAP analysis. There-
fore, 2.5 μM SAHA was used in all subsequentexperiments where the addition of SAHA was neces-
sary to create an assay window.
Full-length, GFP-tagged wild-type and mutant SMARCA2
proteins were localised exclusively in the nucleus, but not
in nucleoli (Figure 3A), consistent with reported sub-
cellular localisation [28]. Photobleached areas recovered
to >95% of their initial intensities, indicating that the
SMARCA2 protein is highly mobile (Figure 4C). t½ in
the wild-type control cells was 3.6 ± 0.1 seconds, which




















































































































































Figure 4 Fluorescence recovery after photobleaching assay utilising a multimerised CREBBP bromodomain construct to establish a robust
assay window. (A) Domain organisation of CREBBP and representation of the regions of CREBBP incorporated into various green fluorescent protein
(GFP) chimeric expression constructs. (B) Half-times of fluorescence recovery (t½) from fluorescence recovery after photobleaching (FRAP) assay using
full-length CREBBP (EX1). (C) Nuclei of U2OS cells transfected with plasmids encoding GFP chimerised to wild-type (wt) or mutant multimerised CREBBP
bromodomain (EX4), with or without 2.5 μM suberoylanilide hydroxamic acid (SAHA) and the inhibitor I-CBP112. The bleached area is indicated by a
red circle. (D) Time dependence of fluorescence recovery in the bleached area of cells expressing wt or mutant EX4. (E) Half-times of fluorescence
recovery (t½) of cells expressing wt or mutant EX4. Bars represent the mean t½ calculated from individual recovery curves of at least ten cells per group,
and error bars depict the standard error of the mean. Where an inhibitor is used, concentration is 1 μM. N####F, Bromodomain mutants, indicating
substitution made. †Addition of 2.5 μM SAHA. *P < 0.05, significant difference from wt†.
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resulted in recovery times indistinguishable from those of
wild-type controls, irrespective of SAHA addition, and the
increase in t½ seen in wild-type cells with the addition of
SAHA was abolished by the SMARCA2 inhibitor PFI-3
[29] (P < 0.05), demonstrating that the assay is sensitive to
small-molecule inhibitors.
Addition of SAHA was also necessary to establish viable
assay windows for BAZ2A [30], BRD7 [31,32], ATAD2
[33], GCN5L2 [34] and ZMYND11 [35,36] (Figure 3D).
For ZMYND11 FRAP, recovery times of bromodomainmutants differed little from those of wild-type controls
and were unchanged by the addition of SAHA, indicating
that the observed increase in wild type t½ in response to
SAHA was mediated solely by the bromodomain. In the
BAZ2A, BRD7, ATD2 and GCN5L2 FRAP assays, there
was a consistent trend for the SAHA-treated mutant cells
to show longer FRAP recovery times compared to the
wild-type or mutant cells, although this difference was not
always significant in ANOVA multiple comparisons test-
ing. This could be due to SAHA-induced global chromatin
acetylation resulting in a shift toward the euchromatin
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tin through non-bromodomain-driven interactions. Despite
this partial response of mutant cells to SAHA treatment, a
clear assay window (P < 0.05) could be seen between the
SAHA-treated wild-type and mutant cells, implying that
these assays would be sensitive to small-molecule inhi-
bitors. Indeed, where such inhibitors have been described
(GSK2801 [37] for BAZ2A and bromosporine [38] for
BRD7), reduced recovery times in the presence of SAHA
back to SAHA-treated mutant control levels were observed
(P < 0.05). Of note is the response of wild-type, but not
mutant, ZMYND11 to SAHA, since ZMYND11 has an
atypical bromodomain that does not contain the conserved
asparagine present in all of the other bromodomains
examined here, but rather a tyrosine, suggesting that
FRAP assays may also be applicable to other atypical
bromodomain-containing proteins.
When BRD1 [39] was first evaluated for FRAP under
the same conditions as those in other assays, GFP-tagged
BRD1 appeared to be localised exclusively to distinct
nuclear speckles, without any diffuse distribution across
the nucleus, consistent with reported immunohistological
staining results [40]. Attempted FRAP assays with these
cells produced almost no recovery after photobleaching
(data not shown), indicating that BRD1 is almost entirely
immobilised in these speckles within the time frame of the
FRAP experiments. Speckling was observed with both
wild-type and mutant BRD1 and was unaffected by the
addition of SAHA, suggesting that this distribution is not
being driven by the bromodomain. However, when micro-
scope gain settings were increased to >850 to allow visua-
lisation of cells expressing very low levels of GFP-BRD1,
cells with a homogeneous distribution of tagged protein
could be observed. Initial experiments with these cells
showed an appreciable immobile fraction (approximately
20%), and no difference in t½ was observed between cells
expressing wild-type or mutant BRD1 in the absence of
SAHA (data not shown). However, the FRAP recovery
time of wild-type cells, but not mutant cells, was signifi-
cantly increased (P < 0.05) by the addition of SAHA
(Figure 3D), indicating that a viable FRAP assay is pos-
sible if only cells with low levels of BRD1 expression are
selected.
In the FRAP assays for BRD3 and BRD4, both of which
contain two bromodomains, assays sensitive to small-
molecule inhibitors were possible without the addition of
SAHA. However, although there was a trend in both
assays for mutation of the first bromodomain to produce a
greater reduction in t½ than the second, which would be
consistent with in vitro affinity studies [41,42], these diffe-
rences failed to reach significance in ANOVA multiple
comparisons testing. In an attempt to improve the sensi-
tivity of these assays, a BRD3 FRAP assay was performed
with the addition of SAHA, which resulted in a clearsignificant difference (P < 0.05) between the N115F and
N390F mutants (Figure 3E). Furthermore, the assay was
able to differentiate between the inhibitors RVX0208,
which is reported to inhibit primarily the second domain
of BRD3 [41,42] and produces a t½ almost identical to that
of the N390F mutant, and PFI-1, which is active against
both bromodomains and reduces t½ to a much greater
extent. Use of these inhibitors at the higher dose of 5 μM
ensures that differences are due to selective targeting of
the bromodomains rather than to differences in potency.
CREBBP, and its paralog EP300, are involved in many
physiological processes, including proliferation, differenti-
ation and apoptosis [43]. Both act as transcriptional co-
activators for a large number of transcription factors and
exhibit chromatin-remodelling properties through rela-
xation of chromatin through intrinsic HAT activity [44].
FRAP experiments with full length CREBBP produced no
discernable difference in recovery time between the wild
type and the bromodomain mutants (Figure 4B). Further-
more, addition of SAHA did not increase the t½ of wild-
type cells, and the system was unresponsive to inhibitors.
The moderately long t½ of 14.9 ± 1.1 seconds for the wild-
type control cells indicates that CREBBP is binding to
chromatin, but the lack of effect of bromodomain muta-
tion or either SAHA or inhibitor addition suggests that
the CREBBP bromodomain is not a major driver of this
interaction. Indeed, CREBBP possesses several other chro-
matin binding domains (Figure 1A), including two TAZ
zinc finger domains, a KIX domain, a ZZ-type zinc finger
domain and the CREB binding domain, all of which are
involved in binding to other transcription factors [45-48],
as well as the HAT domain that acetylates histone and
nonhistone proteins [49]. Together, all of these chroma-
tin interactions could be masking any contribution by
the bromodomain.
To isolate chromatin–bromodomain interactions from
other CREBBP binding domains, a number of expression
constructs were made (Figure 4A) with either N- or C-
terminal GFP fusions. However, transfection of constructs
with C-terminal GFP was poorly tolerated by cells, causing
high levels of cytotoxicity. Therefore, only results from
transfections with N-terminal GFP are presented. A fusion
protein of GFP linked to the N-terminus of the CREBBP
bromodomain (amino acids 1,087 to 1,194) was not loca-
lised exclusively within the nucleus (data not shown) and
was unsuitable for FRAP. Addition of the nuclear localisa-
tion sequence (NLS) from simian virus 40 (SV40) large T
antigen between the GFP and the CREBBP bromodomain
(Figure 4A, EX2) resulted in exclusively nuclear localisa-
tion, but the recovery time was rapid and the addition of
SAHA resulted in only a moderate increase of FRAP
recovery time. Furthermore, the assay was insensitive to
inhibitor compounds (data not shown), possibly due to
steric hindrance by the adjacent GFP tag. A larger
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(amino acids 868 to 1,341) and including a NLS
(Figure 4A, EX3) also resulted in a very small assay
window upon addition of SAHA (data not shown). To
improve this assay window, we hypothesised that tandem
repeats of the CREBBP bromodomain, like those seen in
BET family members, might increase the apparent affinity
of the chimeric CREBBP bromodomain protein for chro-
matin. An expression construct with N-terminal GFP and a
NLS followed by three tandem repeats of the same amino
acid sequence used in EX3 (Figure 4A, EX4) produced
rapid recovery in FRAP with a t½ of 1.1 ± 0.1 seconds in
wild-type control cells. Further reduction in recovery times
was not seen when all three tandem repeats harboured the
mutation corresponding to N1168F in full-length CREBBP
(P > 0.05), but a substantial increase in the wild type was
seen with the addition of SAHA (2.5 ± 0.1 seconds; P <
0.05). This increase was abolished in the bromodomain
mutants (P < 0.05) and by addition of the inhibitor I-
CBP112 at 1 μM [50] (P < 0.05), demonstrating that
the tandem repeat construct provided both a good
assay window and sensitivity to inhibitors.
To ascertain that selective inhibitors tested in FRAP
experiments do not cross-react with other bromodomains
in the cellular environment, the BET inhibitor PFI-1 was
profiled across 10 bromodomain targets in FRAP assays at
1 μM. Significant reductions (P < 0.05) in FRAP recovery
times relative to wild-type controls were observed only for
the BET family members BRD3 and BRD4 (Figure 5). This
finding is consistent with reported in vitro selectivity [18],
demonstrating that the FRAP assays exhibit good selec-







































































Figure 5 Selectivity of fluorescence recovery after
photobleaching assays. Half-times of fluorescence recovery (t½)
expressed as a percentage of the relevant wild-type control cells
without inhibitor. Cells were transfected with the indicated
bromodomain target and treated with 1 μM PFI-1. Light bars depict
assays without suberoylanilide hydroxamic acid (SAHA) addition, and
dark bars depict assays with SAHA addition (2.5 μM). The dotted line
demarks the point equivalent to 100% of the relevant wild-type
control cells without inhibitor. Error bars depict the standard error of
the mean. Only bars marked with an asterisk indicate a significant
difference from controls (P < 0.05).Of the 42 bromodomain-containing proteins, subcellular
localisation information is available for 29 of them in the
Human Protein Atlas [40]. All but two of these proteins
are found in the nucleus, although many, including BRD3,
BRD4, TRIM24 and particularly BRD1, exhibit a granular,
or even speckled, distribution. However, we have shown
here that viable FRAP assays are still possible with these
targets. BAZ1A and BRPF1, both of which are highly
expressed in the testes, where they localise to the nucleus
[51,52], appear to be largely excluded from the nuclei of
cell lines, including U2OS cells [40], precluding FRAP
assays with full-length proteins in common cell lines.
These targets may be candidates for assays utilising bro-
modomain tandem repeats with the addition of a NLS,
although the biological relevance of forcing these isolated
bromodomains into the nucleus is questionable.Conclusions
Many bromodomains have identified roles in human dis-
ease, including cancer, inflammation and neurological
disease, while the function and disease involvement of
others remains unclear. This makes bromodomains at-
tractive targets for chemical probe and novel thera-
peutic development. A key step in the drug discovery
process is demonstration of cell permeability and
in vivo efficacy. The 11 representative FRAP assays for
bromodomain-containing proteins described here are
distributed across the phylogenetic tree (Figure 1B) and
demonstrate that FRAP cell-based assays are broadly
applicable across this class of proteins, indicating that
the method will be suitable for many other family mem-
bers. Generation of bromodomain mutant controls can
establish assay efficacy even in advance of inhibitor de-
velopment. In situations where the binding contribution
of the bromodomain is masked by other, stronger do-
mains, the use of artificial tandem repeat constructs al-
lows viable assays to be developed. These assays directly
interrogate bromodomain binding to chromatin, not a
downstream surrogate marker, while the short incu-
bation time allows for measurement of bromodomain
displacement only and not secondary effects due to sub-
sequent inhibitor-induced changes in gene expression.
Importantly, these assays can be implemented without
the need for detailed knowledge of the function of the
bromodomain-containing protein, which is lacking for
many members of this family. Thus, FRAP assays offer a
potentially universal method for generating cell-based
assays for bromodomain-containing proteins that allow
compounds to be tested for cell permeability and on-
target efficacy. The method is also likely to be applicable
to proteins containing other classes of epigenetic reader
domains, including Tudor, PHD, chromo and MBT
repeat domains.
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Plasmids
The full-length cDNA clone for human BRD4 [GenBank:
NM_058243.2] was a gift from James Bradner (Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston,
MA, USA). Full-length cDNAs were obtained as I.M.A.G.E.
clones from Source BioScience Life Sciences (Nottingham,
UK) for ATAD2 [IMAGE:8322708] [GenBank:BC113656],
BAZ2A [IMAGE:100015975] [GenBank:BC152739], BRD1
[IMAGE: 100000034] [GenBank:CU013256], BRD3 [IMAGE:
4015879] [GenBank:BC031536], BRD7 [IMAGE:100066308]
GenBank:BC166008], SMARCA2 [IMAGE:100061549] [Gen-
Bank:BC156185], TRIM24 [IMAGE:5698079] [GenBank:
BC056959] and ZMYND11 [IMAGE:100003947] [GenBank:
DQ891317]. Full-length cDNA for CREBBP [pFIKB0067]
[GenBank:AB527452] was obtained from the Kazusa
ORFeome Project (Kazusa DNA Research Institute, Kisarazu,
Japan) [53]. Human clones were preferentially sourced
(ATAD2, BAZ2A, BRD4, CREBBP, SMARCA2 and
ZMYND11), but where this was not possible, mouse clones
were used (BRD3, BRD7 and TRIM24). Where mouse
clones were used, the amino acid sequences were >97%
identical in the bromodomain region in all cases (see
Additional file 2: Figure S2).
I.M.A.G.E. clones for BAZ2A, BRD1, BRD7 and
SMARCA2 were in the pDONR223 backbone [54]. The
I.M.A.G.E. clone for ZMYND11 was in the pDONR221
backbone (Life Technologies, Carlsbad, CA, USA). For
the remaining targets, each full-length gene was PCR-
amplified (AccuPrime Pfx DNA Polymerase; Life Tech-
nologies) from the start codon to the stop codon with
primers that included the appropriate attB sequences.
PCR products were cloned with Gateway BP Clonase II
enzyme mix (‘BP-cloned’ henceforth; Life Technolo-
gies) into either pDONR221 or pDONR223 to create
entry clones (see Additional file 3: Table S1 for details
of primers and DONR vectors). The gene of interest
was then shuttled into either pcDNA5/FRT/TO-eGFP-
DEST [55] (ATAD2, BAZ2A, BRD1, BRD7, CREBBP,
SMARCA2, TRIM24 and ZMYND11) or pcDNA6.2/N-
EmGFP-DEST (BRD3, BRD4 and GCN5L2) by cloning
with the Gateway LR Clonase II Plus enzyme mix (‘LR-
cloned’ henceforth; Life Technologies) to create chimeric
GFP expression clones (see Additional file 4: Table S2).
Corresponding bromodomain mutant expression clones
were generated using the megaprimer PCR method [56],
taking advantage of either flanking restriction enzyme sites
or att sites in the template. The exact position of the
mutated residue is shown in Supplementary Figure 1. For
cloning using flanking restriction enzyme sites, a first
round of PCR using a primer outside the flanking region
and a mutagenic primer with at least 10 base pairs (bp) of
matching sequence on either side of the desired mutation
was used to generate a megaprimer. A second round ofPCR using the megaprimer and a primer beyond the
opposite restriction site was used to generate a product
flanked by both restriction sites and carrying the desired
mutation. Both the PCR product and the original expres-
sion clone were digested with the appropriate restriction
enzymes (New England Biolabs, Ipswich, MA, USA) and
gel-purified. The expression clone was further treated
with Antarctic phosphatase (New England Biolabs), before
ligation with the PCR product by T4 DNA ligase (New
England Biolabs) to create mutant chimeric GFP expres-
sion clones. I.M.A.G.E. clones for BAZ2A and SMARCA2
lacked stop codons. Therefore, the derived expression
clones were subjected to a prior round of mutagenesis to
introduce stop codons. Details of templates, primers,
restriction enzymes and resulting expression clones are
summarised in Additional file 5: Table S3. For cloning
using flanking att sites, a first round of PCR using a pri-
mer outside the flanking region and a mutagenic primer
with at least 10 bp of matching sequence on either side of
the desired mutation was used to generate a megaprimer.
The decision whether the mutagenic primer was the sense
or antisense primer was determined by the position of the
mutation site so as to generate the smaller of the two
possible megaprimers. A second round of PCR using the
megaprimer and a primer beyond the second att site was
used to generate a product flanked by both att sites and
carrying the desired mutation. PCR products generated
from pENTR templates were LR-cloned directly into
pcDNA6.2/N-EmGFP-DEST to create chimeric GFP ex-
pression clones. PCR products generated from pDEST
templates were BP-cloned into pDONR221, before sub-
sequent LR cloning into pcDNA6.2/N-EmGFP-DEST,
to create mutant chimeric GFP expression clones.
Details of the templates, primers and cloning vectors
used are summarised in Additional file 6: Table S4.
A CREBBP multimerised bromodomain construct was
made using the MultiSite Gateway System [57] (Life Tech-
nologies). Three Gateway entry clones were created for
both the wild-type and bromodomain mutant CREBBP
that encompassed the region corresponding to RefSeq
amino acids 868 to 1,341. The first entry clone also har-
boured the NLS from the SV40 large T antigen and was
made by two rounds of PCR, the first using a sense primer
incorporating the NLS and wild-type or mutant pcDNA5/
FRT/TO-eGFP-DEST/CREBBP described above as the
template and the second to add the appropriate attB sites
to the PCR product, followed by BP cloning into the
pDONR221 P1-P4 vector. The second and third entry
clones did not carry NLS and were made directly by PCR
amplification of wild-type or mutant pcDNA5/FRT/
TO-eGFP-DEST/CREBBP with primers incorporating
the appropriate attB sequences, followed by BP cloning
into corresponding pDONR221 vectors. See Additional
file 7: Table S5 for details of the primers and DONR
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mutant CREBBP bromodomain were combined by LR
cloning into the pcDNA6.2/N-EmGFP-DEST vector to
create an expression clone for three tandem repeats of the
bromodomain fused to an N-terminal GFP (see Additional
file 8: Table S6).
All constructs described are available upon request.
Fluorescence recovery after photobleaching
FRAP studies were performed using a protocol modified
from previous studies [17,18]. In brief, U2OS cells were
reverse-transfected (Lipofectamine 2000 transfection re-
agent; Life Technologies) with mammalian overexpression
constructs encoding bromodomain-containing proteins
fused to GFP (wild type or mutants). Medium was replaced
6 hours after transfection with or without 2.5 μM SAHA,
and 1 μM inhibitor was added 1 hour before imaging,
which was carried out 24 hours after transfection. The
FRAP and imaging system consisted of a Zeiss LSM 710
scan head (Zeiss GmbH, Jena, Germany) coupled to an
inverted Zeiss Axio Observer.Z1 microscope equipped with
a high numerical aperture (NA 1.3) 40× oil-immersion
objective (Zeiss GmbH) and a heated chamber set at 37°C.
Bleaching and GFP fluorescence imaging were carried out
with an argon ion laser (488 nm) and a photomultiplier
tube detector set to detect fluorescence between 500 and
550 nm. Cells with very high levels of GFP expression
(saturation at gain settings >650) often displayed aberrant
morphology and/or might be expected to have large pools
of free GFP-tagged protein due to saturation of potential
binding sites and were, therefore, excluded from selection
for bleaching. Cells with very low levels of GFP expression
requiring high gain settings (>850) resulted in noisy images
and were particularly susceptible to photobleaching during
imaging and were, therefore, also excluded from selection
for bleaching. Thus, cells with nuclei just below saturation
within the gain range of 650 to 850 were chosen for bleach-
ing. A circular region of a GFP-positive nucleus was
selected, and, after five prescans, the region was bleached.
The size of the bleach area was altered for different
bromodomain-containing proteins between 2.5 μm2 and
17.6 μm2 to keep t½ within a practical range of 1 to 30 se-
conds. A time-lapse series was then taken to record GFP
recovery. During the time-lapse series, images were
acquired with a frame size of 512 pixels × 512 pixels with
line-stepping of 2, bidirectional scanning and a zoom factor
of 6, which allowed for a time interval time of approxi-
mately 0.25 seconds. To decrease the level of photobleach-
ing during acquisition, the laser was attenuated to just 1%
of power used for bleaching, but with the pinhole diameter
set to 1.39 airy units to improve detection of fluorescence.
The average intensity at each imaging time point was
measured for three regions: the bleached region (F(t)ROI),
the total cell nucleus (F(t)total) and a random regionoutside the cell for background subtraction (F(t)BG). The
image data sets were exported from ZEN 2010 microscope
control software (Zeiss GmbH) as text (.txt) files. The text
files were batch-imported into OriginPro 9.1 software
(OriginLab, Northampton, MA, USA) using a custom
LabTalk script that performed all subsequent analysis. The
relative fluorescence signal in the bleached region of each
cell was calculated for each time point (t) with correction
for photobleaching during image acquisition made using
the method of Phair et al. [58], shown in equation 1, where
F(i) is the mean intensity of a region in the five prebleach
scans.
F tð Þnorm ¼
F tð ÞROI − F tð ÞBG
F tð Þtotal − F tð ÞBG
 F ið Þtotal − F ið ÞBG
F ið ÞROI − F ið ÞBG
ð1Þ
Double exponential association curves were fitted to the
normalised data using the OriginPro function ExpAssoc,
which has the formula shown in equation 2.





Using parameters returned by the curve-fitting, the
fluorescence intensity corresponding to half-recovery was
calculated using equation 3.
y1=2 ¼ y0þ A1þ A2
2
ð3Þ
An iterative bisection algorithm was then used to
determine the value of x (that is, time for half recovery,
or t½) in equation 2 when y = y½.
Because equation 1 normalises data to prebleach
intensities, plateaus from curve-fitting should not be >1.
However, focal drift during FRAP could shift plateaus sub-
stantially above 1, and cells which moved during FRAP or
out of focus debris passing over the cell during imaging re-
sulted in irregular recovery profiles and poor curve-fitting.
Therefore, cells where curve-fitting gave plateaus >1.1 or
adjusted R2 values <0.95 were removed from further ana-
lysis as imaging artefacts. Outliers within a treatment
group were eliminated using the Grubbs test [59] before
the calculation of the arithmetic mean of each treatment
group. One-way ANOVA with Tukey–Kramer correction
for multiple comparisons was used to detect significant
differences (P < 0.05) between treatment groups.
Additional files
Additional file 1: Figure S1. Suberoylanilide hydroxamic acid dose
response. Effect of SAHA concentration on FRAP recovery time in U2OS
cells transfected with plasmids encoding GFP chimerised to wild-type or
mutant SMARCA2. *P < 0.05, significant difference from wt.
Additional file 2: Figure S2. Alignment of bromodomain protein
sequences. Where murine genes have been used for FRAP constructs,
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position of mutagenesis.
Additional file 3: Table S1. Primer and pDONR details for BP cloning.
Additional file 4: Table S2. LR cloning of full-length GFP chimeric
constructs.
Additional file 5: Table S3. Primer details for mutagenesis and
restriction enzymes used for cloning.
Additional file 6: Table S4. Primer details for mutagenesis and pDEST
used for LR cloning.
Additional file 7: Table S5. Primer and pDONR details for generation
of multimerised CREBBP bromodomain construct.
Additional file 8: Table S6. Details of LR cloning of multimerised
bromodomain constructs.
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